Shares of Allergy Therapeutics plc (LON:AGY – Get Free Report) fell 8.9% during mid-day trading on Tuesday . The stock traded as low as GBX 5.87 ($0.07) and last traded at GBX 6.25 ($0.08). 478,628 shares traded hands during mid-day trading, an increase of 5% from the average session volume of 454,540 shares. The stock had previously closed at GBX 6.86 ($0.09).
Allergy Therapeutics Stock Down 8.9 %
The company has a market cap of £307.19 million, a price-to-earnings ratio of -6.02, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40. The company has a current ratio of 1.63, a quick ratio of 1.48 and a debt-to-equity ratio of 835.48. The firm’s fifty day moving average price is GBX 6.71 and its 200-day moving average price is GBX 5.48.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Featured Stories
- Five stocks we like better than Allergy Therapeutics
- How Technical Indicators Can Help You Find Oversold Stocks
- Airbnb’s Earnings: Sky High Results, Grounded Guidance?
- Short Selling: How to Short a Stock
- Kyndryl Soars on AI, Cybersecurity Growth—What’s Next?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Conflicting Signals: Tempus AI’s Stock Market Rally
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
